This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma，aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab and famitinib . Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody, and famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.

Start Date19 Jul 2021

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

CTR20160581 / CompletedPhase 2

评价沃利替尼治疗肺肉瘤样癌和其他非小细胞肺癌患者的有效性、安全性和耐受性的多中心、开放II期临床研究

[Translation] A multicenter, open-label phase II clinical study to evaluate the efficacy, safety, and tolerability of savolitinib in the treatment of patients with pulmonary sarcomatoid carcinoma and other non-small cell lung cancer

1、评价沃利替尼治疗局部晚期或转移性肺肉瘤样癌患者的客观缓解率（ORR）；2、评价沃利替尼治疗局部晚期或转移性肺肉瘤样癌患者的无进展生存期（PFS）；3、评价沃利替尼治疗的局部晚期或转移性肺肉瘤样癌患者的疾病控制率（DCR），缓解期（DoR）（RECIST1.1标准）和生存期（OS）；4、评价沃利替尼治疗局部晚期或转移性肺肉瘤样癌患者的安全性和耐受性。

[Translation]

1. To evaluate the objective response rate (ORR) of savolitinib in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma; 2. To evaluate the progression-free survival (PFS) of savolitinib in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma; 3. To evaluate the disease control rate (DCR), duration of response (DoR) (RECIST1.1 standard) and overall survival (OS) of savolitinib-treated patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma; 4. To evaluate the safety and tolerability of savolitinib in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma.

Start Date08 Nov 2016

Sponsor / Collaborator

Hutchison MediPharma Ltd.

100 Clinical Results associated with Pulmonary sarcomatoid carcinoma

100 Translational Medicine associated with Pulmonary sarcomatoid carcinoma

0 Patents (Medical) associated with Pulmonary sarcomatoid carcinoma

Literatures (Medical) associated with Pulmonary sarcomatoid carcinoma

01 Dec 2024·Oncology letters

3D‑printed template‑guided iodine‑125 seed implantation to treat complete occlusion of the superior vena cava in pulmonary sarcomatoid carcinoma: A case report.

Article

Author: Di, Xuemin ; Gao, Zhen ; Yu, Huimin ; Liang, Yansong ; Liu, Xiaoli ; Zhao, Jinxin ; Zhang, Hongtao

Pulmonary sarcomatoid carcinoma (PSC), which is a type of non-small-cell lung carcinoma (NSCLC), is characterized by a high degree of malignancy, poor differentiation and a high incidence of pulmonary malignancy. In addition, PSC has a stronger invasive ability than other types of NSCLC and is not sensitive to radiation or chemotherapy. Furthermore, 90% of PSC cases exhibit vascular invasion; therefore, there is a risk of multiple metastases to the lung, bone, adrenal glands and brain, and consequently a poor prognosis, in the early stage. Targeted therapy and immunotherapy currently offer a new treatment direction; however, there have not been any significant advances in localized treatment in recent years. Thus, there is an urgent need for new localized treatment strategies. The present study describes the case of a 65-year-old man with recurrence of PSC after multi-line treatment with chemotherapy, radiotherapy, gamma knife and argon-helium knife treatment. In addition, the patient developed superior vena cava syndrome, and exhibited severe compression of the superior vena cava, chest discomfort, dyspnea and severe facial edema after chemotherapy, local gamma knife therapy (35 Gy, delivered through 14 2.5-Gy doses), argon-helium knife therapy and radiation therapy (28 Gy, delivered through seven 4-Gy doses). Partial remission was achieved after local implantation of iodine-125 (I¹²⁵) seed under the guidance of a 3D-printed template, with progression-free survival observed up to 8 months afterwards. In conclusion, in patients with PSC who develop superior vena cava blockage after numerous treatment regimens, salvage I¹²⁵ brachytherapy with a 3D-printed template may be suitable, and may improve local control and symptoms.

01 Sep 2024·European Journal of Cancer

Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors

Article

Author: Cai, Xiuyu ; Chu, Tianqing ; Zhu, Bo ; Wu, Lin ; Xie, Mengqing ; Zhou, Caicun ; Yao, Yu ; Dong, Xiaorong ; Wang, Huijuan ; Wang, Jialei ; Chu, Qian ; Ye, Feng ; Su, Chunxia

BACKGROUNDImmune checkpoint inhibitors (ICIs) have improved the prognosis of patients with non-small cell lung cancer but rarely been explored in pulmonary sarcomatoid carcinoma (PSC). This multicenter study aimed to evaluate the effectiveness of ICIs for PSC and its underlying mechanism.METHODSAdvanced PSC who received ICIs between August 2018 and May 2022 from 11 centers in China were included. Clinical characteristics and treatment information were collected. Whole-exome sequencing (WES) and whole transcriptome sequencing were conducted on pre-treatment samples to explore the mechanism.RESULTS113 patients with PSC were enrolled, the median PFS for patients receiving ICIs therapy was 8.77 months (95 % confidence interval, 4.21 to 13.32). Combining ICIs with anti-angiogenic agents significantly increased PFS (p = 0.04). Liver metastasis and combination therapy with anti-angiogenic agents were independent risk factors for PFS (Hazard Ratio [HR] = 3.652, p = 0.019 and HR = 0.435, p = 0.017, respectively). WES showed that PSC presented with a TMB of 6.3 mutations per million base pairs. High expression of TNFα signaling and glycolysis related gene showed a better prognosis.CONCLUSIONSICIs showed promising benefits for advanced PSC, and the addition of anti-angiogenic therapy might be a more effective treatment strategy for this disease.

01 Sep 2024·Translational Lung Cancer Research

Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

Article

Author: Cremer, Isabelle ; Leroy, Karen ; Fabre, Elizabeth ; Wislez, Marie ; Damotte, Diane ; Alifano, Marco ; Raynaud-Donzel, Christine ; Chapron, Jeanne ; Girard, Nicolas ; Monnet, Isabelle ; Arrondeau, Jennifer ; Birsen, Gary ; Giroux Leprieur, Etienne ; Cadranel, Jacques ; Gounant, Valérie

BackgroundPulmonary sarcomatoid carcinomas (PSC) are notorious for their poor prognosis and resistance to chemotherapy. The literature suggests that immunotherapy might be effective against this aggressive tumor. This study aims to evaluate the efficacy of immunotherapy, either alone or combined with chemotherapy, as first-line treatment for PSC patients.MethodsIn a retrospective, multicentric, real-world study conducted between July 2017 and April 2021, patients with stage III (ineligible for surgery or radio-chemotherapy) or stage IV PSC were enrolled. These patients received their first-line treatment with immunotherapy and were categorized into two groups based on their treatment modality: the immuno-chemotherapy (IO CT) group or the immunotherapy-alone (IO) group.ResultsThis study analyzed a population of 34 patients from eight different hospital centers. In this cohort, the objective response rate (ORR) was 56%, median duration of response was 20.5 months, median progression-free survival (PFS) was 5.11 months, and median overall survival (OS) 13.9 months. Demographic characteristics remained consistent among the treatment groups except for the age (54.0- and 71.0-year-old in the IO CT and IO group, respectively, P=0.02). The IO CT group demonstrated an ORR of 64.0%, a median PFS at 8.72 months, and a median OS of 16.08 months, while the IO group displayed respective values of 52.0%, 3.45 months, and 13.11 months.ConclusionsThis study showed the potential efficacy of immunotherapy as a first-line treatment for PSC. While acknowledging the retrospective nature of the study, our findings suggest a trend favoring the combination of IO CT over IO alone in these patients.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Pulmonary sarcomatoid carcinoma

Basic Info

Related

Analysis